Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Debt to Equity (2022 - 2025)

Taysha Gene Therapies' Debt to Equity history spans 4 years, with the latest figure at $0.23 for Q3 2025.

  • For Q3 2025, Debt to Equity fell 52.01% year-over-year to $0.23; the TTM value through Sep 2025 reached $0.23, down 52.01%, while the annual FY2024 figure was $0.61, 13.65% up from the prior year.
  • Debt to Equity for Q3 2025 was $0.23 at Taysha Gene Therapies, up from $0.17 in the prior quarter.
  • Across five years, Debt to Equity topped out at $40.01 in Q4 2022 and bottomed at -$3.65 in Q3 2023.
  • The 4-year median for Debt to Equity is $0.54 (2023), against an average of $2.81.
  • The largest annual shift saw Debt to Equity crashed 446.49% in 2023 before it skyrocketed 133.63% in 2024.
  • A 4-year view of Debt to Equity shows it stood at $40.01 in 2022, then crashed by 98.65% to $0.54 in 2023, then grew by 13.65% to $0.61 in 2024, then plummeted by 62.2% to $0.23 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Debt to Equity are $0.23 (Q3 2025), $0.17 (Q2 2025), and $0.77 (Q1 2025).